Savi L et al. – These results need to be confirmed by randomized, double–blind, prospective, large clinical trials. Methods
|
| The endocannabinoid system in anxiety, fear memory and habituation Journal of Psychopharmacology, 08/19/11 |
| Ruehle S et al. – In fear memory paradigms, the endocannabinoid system (ECS) is mostly involved in the two opposing processes of reconsolidation and extinction of the fear memory. Whereas ECS activation deteriorates reconsolidation, proper extinction depends on intact cannabinoid type 1 (CB1) receptor signalling. Thus, both for anxiety and fear memory processing, endocannabinoid signalling may ensure an appropriate reaction to stressful events. Therefore, the ECS can be considered as a regulatory buffer system for emotional response |
| Treatment of severe borderline personality disorder with clozapine Indian Journal of Psychiatry, 11/02/10 |
| Vohra AK – Patients with borderline personality disorder (BPD) show significant impairment in the domain of interpersonal and social functioning and may use the resources of health and social services extensively, with little beneficial outcome. At present there are no clear guidelines in literature for the use of pharmacotherapy in the management of BPD. According to the scanty literature available in the form of case reports and small studies, clozapine has been demonstrated to be effective in the management of BPD. |
| Oral versus depot antipsychotic drugs for schizophrenia--A critical systematic review and meta-analysis of
randomised long-term trials Schizophrenia Research, 02/08/11 |
| Leucht C et al. – Non–adherence is a major problem in the treatment of schizophrenia. Depot antipsychotic drugs are thought to reduce relapse rates by improving adherence, but a systematic review of long–term studies in outpatients is not available. Depot antipsychotic drugs significantly reduced relapse. Due to a number of methodological problems in the single trials the evidence is, nonetheless, subject to possible bias. |
| Treatment-Refractory Generalized Anxiety Disorder Psychiatric Annals, 02/21/11 |
| Starcevic V et al. – It has been reported that about half of patients
with generalized anxiety disorder (GAD) do not respond adequately to standard pharmacological treatments, including selective serotonin reuptake inhibitors (SSRIs), serotonin and
norepinephrine reuptake inhibitors (SNRIs), and imipramine, with or without a benzodiazepine. |
|
Clinical potential of lurasidone in the management of schizophrenia |
Samalin L et al. - The efficacy of lurasidone with regard to cognitive functions and depressive symptoms seems good, but requires further work. Lurasidone differs from the other
second-generation antipsychotics by having a good tolerability profile, in particular for cardiometabolic tolerability. However, it seems to have a significant although moderate link with
the occurrence of akathisia, extrapyramidal symptoms, and hyperprolactinemia at the start of treatment. This tolerance profile greatly broadens the scope of second-generation antipsychotics
and so supports the view of some authors that the term ?second-generation antipsychotic? is now outdated.
|
| Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based
cohort study British Journal of Psychiatry, 07/27/11 |
Kessing LV et al. ? In daily clinical practice, treatment with lithium seems in general to be superior to treatment with valproate. Methods
|
| Benzodiazepine Use Among Patients With Schizophrenia in Taiwan: A Nationwide Population-Based Survey Psychiatric Services, 08/10/11 |
| Wu CS et al. – The study showed that benzodiazepine use was highly prevalent among patients with schizophrenia in Taiwan and that a substantial proportion of users (62.9%) were long–term users. Because long–term use was associated with longer duration of illness and with use of concomitant psychotropic medications, long–term users may be at higher risk of neurocognitive side effects caused by benzodiazepines and interactions with other psychotropic medications. Therefore, this group should be closely monitored for drug–drug interactions and the benefits and risks of benzodiazepine use. |
| What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A
naturalistic open-label study International Clinical Psychopharmacology, 08/11/11 |
Shim G et al. ? These results imply that doses less than or equal to 40 mg/day ESC are sufficient for symptomatic improvement with good tolerability for most patients. Very high doses of
ESC, on the other hand, can be considered for patients with inadequate therapeutic responses to the administration of 40 mg/day ESC. Methods
|
| What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A
naturalistic open-label study International Clinical Psychopharmacology, 08/11/11 |
Shim G et al. ? These results imply that doses less than or equal to 40 mg/day ESC are sufficient for symptomatic improvement with good tolerability for most patients. Very high doses of
ESC, on the other hand, can be considered for patients with inadequate therapeutic responses to the administration of 40 mg/day ESC. Methods
|
| Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a
double-blind, placebo-controlled 26-week study International Clinical Psychopharmacology, 08/16/11 |
| Greist JH et al. – The results of this study suggest that pregabalin
(450 mg/day) is safe, well tolerated, and has significant relapse–prevention efficacy over 26 weeks in patients with social anxiety disorder (SAD) who responded to an initial course of
the pregabalin treatment. |
| Tolerability profile of aripiprazole in patients with Tourette syndrome Journal of Psychopharmacology, 08/16/11 |
| Cavanna AE et al. – The discontinuation rate of 20.7% suggests that aripiprazole is safe and reasonably well tolerated for use in TS. The prevalence of adverse effects appears to increase with treatment duration. |
No comments:
Post a Comment